|
Name |
13-Ethenyl-19-hydroxy-5,7,9,11-tetramethyl-2-oxa-18-azahexacyclo[19.2.2.13,10.116,19.04,9.014,27]heptacosa-1(23),11,21,24-tetraene-15,17-dione
|
Molecular Formula | C31H39NO4 | |
IUPAC Name* |
13-ethenyl-19-hydroxy-5,7,9,11-tetramethyl-2-oxa-18-azahexacyclo[19.2.2.13,10.116,19.04,9.014,27]heptacosa-1(23),11,21,24-tetraene-15,17-dione
|
|
SMILES |
CC1CC(C2C3C4C(C(C=C(C4C2(C1)C)C)C=C)C(=O)C5CC(CC6=CC=C(O3)C=C6)(NC5=O)O)C
|
|
InChI |
InChI=1S/C31H39NO4/c1-6-20-12-18(4)25-24-23(20)27(33)22-15-31(35,32-29(22)34)14-19-7-9-21(10-8-19)36-28(24)26-17(3)11-16(2)13-30(25,26)5/h6-10,12,16-17,20,22-26,28,35H,1,11,13-15H2,2-5H3,(H,32,34)
|
|
InChIKey |
OCUONUXNKYDHKY-UHFFFAOYSA-N
|
|
Synonyms |
Pyrrocidine B; BS-1234
|
|
CAS | NA | |
PubChem CID | 129008868 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 489.6 | ALogp: | 5.5 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 75.6 | Aromatic Rings: | 7 |
Heavy Atoms: | 36 | QED Weighted: | 0.423 |
Caco-2 Permeability: | -4.717 | MDCK Permeability: | 0.00011547 |
Pgp-inhibitor: | 0.537 | Pgp-substrate: | 0.007 |
Human Intestinal Absorption (HIA): | 0.043 | 20% Bioavailability (F20%): | 0.116 |
30% Bioavailability (F30%): | 0.008 |
Blood-Brain-Barrier Penetration (BBB): | 0.362 | Plasma Protein Binding (PPB): | 98.27% |
Volume Distribution (VD): | 1.575 | Fu: | 1.66% |
CYP1A2-inhibitor: | 0.034 | CYP1A2-substrate: | 0.9 |
CYP2C19-inhibitor: | 0.73 | CYP2C19-substrate: | 0.913 |
CYP2C9-inhibitor: | 0.472 | CYP2C9-substrate: | 0.162 |
CYP2D6-inhibitor: | 0.039 | CYP2D6-substrate: | 0.458 |
CYP3A4-inhibitor: | 0.907 | CYP3A4-substrate: | 0.838 |
Clearance (CL): | 12.15 | Half-life (T1/2): | 0.016 |
hERG Blockers: | 0.268 | Human Hepatotoxicity (H-HT): | 0.567 |
Drug-inuced Liver Injury (DILI): | 0.901 | AMES Toxicity: | 0.02 |
Rat Oral Acute Toxicity: | 0.998 | Maximum Recommended Daily Dose: | 0.946 |
Skin Sensitization: | 0.024 | Carcinogencity: | 0.035 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
Respiratory Toxicity: | 0.942 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005320 | 0.845 | D0V4WD | 0.227 | ||||
ENC004853 | 0.772 | D0W2EK | 0.220 | ||||
ENC003137 | 0.739 | D0VA0I | 0.216 | ||||
ENC004852 | 0.714 | D0I5DS | 0.210 | ||||
ENC005770 | 0.647 | D04SFH | 0.209 | ||||
ENC003851 | 0.602 | D0F1EX | 0.207 | ||||
ENC003989 | 0.589 | D0E9KA | 0.205 | ||||
ENC003503 | 0.578 | D09WYX | 0.205 | ||||
ENC005769 | 0.485 | D05VQI | 0.202 | ||||
ENC005768 | 0.482 | D08PIQ | 0.201 |